Milestone Scientific (MLSS) Q1 2026 earnings review
Cost Cutting Works, But Growth Remains a 'Show Me' Story
Milestone Scientific delivered on its promise of fiscal discipline in Q1 2026. The operating loss narrowed dramatically to $828,000—a massive improvement from $2.0 million a year ago—driven by a 30%+ reduction in operating expenses. However, top-line growth is stagnant. Revenue dipped slightly to $2.16 million (down 3% YoY) due to Middle East shipping challenges, meaning the company must significantly accelerate sales in the remaining three quarters to hit its reaffirmed $9.8–$10.2 million annual guidance. A recent $2.15 million capital raise buys the company crucial time as it targets cash flow breakeven in early 2027.
🐂 Bull Case
Management has proven they can cut unstructured spending without destroying the core business. Operating expenses dropped by over 30%, and the operating loss halved YoY. The early 2027 breakeven target looks increasingly credible.
CompuFlo revenue more than doubled year-over-year in Q1. As the Advisor program scales with newly established reimbursement support, this high-margin medical segment could become the primary growth engine.
🐻 Bear Case
With Q1 revenue down 3%, achieving the 11% implied full-year growth target ($10.0M midpoint) requires an immediate and sustained sales acceleration in the remaining three quarters.
The company cited Middle East conflict delays as a drag on Q1 sales, and tariffs are actively compressing gross margins (down to 72.3%). External factors are hindering operational momentum.
⚖️ Verdict: ⚪
Neutral. The aggressive cost restructuring is a massive success, significantly extending the cash runway. However, until the top-line actually breaks out of its current flatline, the equity remains a 'show me' turnaround story.
Key Themes
Operating Leverage is Reversing the Cash Burn
The transition from unstructured spending to an ROI-focused model is complete and yielding results. Operating expenses were slashed by over $1.2 million year-over-year in Q1. If management can hold this expense line, any incremental revenue growth in 2026 will drop straight to the bottom line, accelerating the timeline to cash flow breakeven.
CompuFlo Adoption Accelerating
The medical business is officially showing life, with revenue more than doubling year-over-year in Q1. The strategy of building a 'CompuFlo Advisor program' (now over 10 physician partners) backed by dedicated reimbursement infrastructure is working. Management expects this unit to grow ~400% in FY26, shifting the company's dependency away from the legacy dental business.
Execution Risk on H2 Ramp-Up
The math behind the guidance is concerning. Management maintained FY26 revenue targets of $9.8–$10.2 million. Having delivered only $2.16 million in Q1, the company needs to average over $2.6 million per quarter for the rest of the year. This requires the new Dental Ambassador program to scale flawlessly in the face of current stagnation.
Tariffs Pressuring Gross Margins
Gross margin decelerated to 72.3% from 73.8% a year ago. Management explicitly cited tariffs on imported components as a cost pressure. While the Medical segment's growth partially offset this, any further supply chain friction could jeopardize the company's 70%+ structural margin target.
Geopolitical Disruption to Sales
Management noted that Q1 revenue was actively hindered by challenges shipping booked orders to the Middle East due to the ongoing regional conflict. This introduces an unpredictable macro headwind into a timeline that requires consistent quarter-over-quarter sales beats.
Other KPIs
The company ended Q1 with a dangerously low $1.2 million in cash, triggering a 'going concern' warning in the 10-K. However, the subsequent $2.15 million private placement in April ($1.8M cash, $351k debt reduction) provides critical breathing room. Paired with the reduced Q1 cash burn, liquidity risk is mitigated for the immediate future.
Down 5% year-over-year. The combination of slightly lower sales volumes and product mix shifts negatively impacted total gross profit. Margin defense will be crucial as the company pushes volume through new ambassador and advisor channels.
Guidance
Accelerating. The midpoint of $10.0 million implies ~11% growth over FY25's $9.0 million. Given Q1's negative growth, this explicitly relies on the newly launched commercial initiatives hitting their stride in Q2 and Q3.
Stable. Management reaffirmed their commitment to turning cash flow positive by early next year. The math supports this trajectory if operating expenses remain capped at current levels and revenue growth materializes.
Key Questions
Middle East Revenue Recovery
How much revenue was specifically deferred due to Middle East shipping challenges in Q1, and do you expect to recognize those booked orders in Q2?
Gross Margin Defense
With tariffs dragging gross margin down 150 basis points this quarter, do you have pricing power to pass these costs onto customers, or should we model margins closer to 72% for the remainder of the year?
CompuFlo Composition
You noted CompuFlo revenue more than doubled. Can you break down how much of this growth was driven by existing physician utilization versus onboarding new pain clinics from the Advisor program?